38 results about "Clinical evidence" patented technology

A system and related techniques automatically generate optimized, best-match or sufficient assignments of care providers, such as physicians, nurses or technicians, to a patient based on clinical evidence, documentation, workload, infectious status and other factors. In embodiments, the patient's chart or other clinical record may be accessed by a rules-based engine configured with rules which relate a patient's clinical status and needs to the qualifications, certifications, capabilities and skills of care providers and select the care provider best qualified to service that patient's clinical requirements. The pool of available care providers may for example be ascertained from personnel systems recording staff schedules and estimated workload, while the qualifications of each provider indicating the categories of patient care and support that provider is qualified to provide may be accessed from a provider data store. For instance, nurses or technicians trained or certified in acute, emergency or surgical care may be identified for assignment to high acuity patients, or those presenting special or advanced care demands. According to the invention in a further regard, the provider's potential infectious exposure to other patients or from other sources may be screened to prevent that provider from being assigned to immune-compromised or other patients. Embodiments of the invention may present floor managers with a graphical display of available providers and generated assignments, which in embodiments the manager may override at their clinical discretion. Because patient needs are automatically aligned with provider capabilities, availability and other factors, the errors, oversights and inefficiencies of manual or informal assignment systems are avoided and better health care delivery can be realized.

Systems and methods provide visual presentation of clinical evidence to a user in association with a patient's anatomy. In certain examples, a patient information interface system to present an aggregated, graphical view of patient anatomy and history includes a data store to include images and patient history information and a processor to implement a user interface to accept user input. The processor provides a plurality of graphical representations of a human anatomy. Each graphical anatomy representation is to provide a view of a body system. Each graphical anatomy representation is to include one or more indicators corresponding to clinical events that have occurred in connection with a patient in the body system and are viewable through the graphical anatomy representation. Each of the one or more indicators is to be located at an anatomical location on the graphical representation affected by the clinical event corresponding to the indicator.

The invention provides a database for guiding individualized medicine taking of a clinical tumor, a constructing method, a searching method and a device thereof. The constructing method of the database comprises the steps of acquiring common data resources of information of a biomarker which is related to tumor chemotherapy, targeted and immunization medicine taking guidance; screening and classifying the common data resources, and obtaining key field and attribute of biomarker information; performing grade classification and dividing on clinical evidence information; establishing a deciphering database structure framework of the biomarker which is related with tumor chemotherapy, targeting and immunization; and recording the information which corresponds with the key field to the corresponding field position of the database structure framework for obtaining the database for guiding individualized medicine taking of the clinical tumor. According to the method, the multi-layer biomarkers which are detected through detecting technology such as high-flux sequencing and immunocytochemistry are comprehensively considered, thereby covering information at aspects of tumor chemotherapy, targeting and immunization medicine taking guidance, and making knowledge resource reserving for clinical medical guidance for individualized medicine taking of the tumor.

The invention discloses a multi-center knowledge graph joint decision support method and system, which utilizes a medical knowledge graph technology and a block chain technology to realize local semantic reasoning and on-chain result summarizing of clinical data through a mode of combining a local knowledge graph and an on-chain synchronous graph, and therefore, under the condition that original medical data is not out of a hospital, interpretable clinical decision support containing complete clinical evidences of the patient is given based on deductive reasoning and evidence-based medicine by integrating fragmented cross-institution medical data of the patient through the knowledge graph technology. Patient identity information is subjected to anonymous comparison, complete encryption of data in an out-of-hospital link and a matching link is guaranteed, triple node structure information is subjected to coding mapping and asymmetric encryption, the safety of the data in the transmission process is guaranteed, only a participating center with permission can decrypt the data, and the data security and privacy guarantee in the multi-center joint reasoning process are effectively ensured.

Certain embodiments of the present invention provide systems and methods for presentation of clinical evidence to a user. Certain embodiments provide an improved picture archiving and communication system (PACS) including a workflow manager facilitating presentation and diagnostic interpretation of clinical evidence aggregated from a plurality of sources. The PACS also includes a workflow screen including a plurality of presentation panes. Each of the plurality of presentation panes displays clinical evidence from the workflow manager according to a particular perspective. The plurality of presentation panes are independent but coordinated, and each of the plurality of presentation panes is context sensitive.

A clinical documentation improvement (CDI) smart scoring method may include predicting, via per-condition diagnosis machine learning (ML) models and based on clinical evidence received by a system, a probability that a medical condition is under-documented and, via per-condition documentation ML models and based on documentation received by the system, a probability that a medical condition is over-documented. The under- and over-documentation scores are combined in view of special indicators and queryability factors, which can also be evaluated using ML query prediction models, to generate an initial CDI score. This CDI score can be further adjusted, if necessary or desired, to account for factors such as length of stay, payer, patient location, CDI review timing, etc. The final CDI score can be used to prioritize patient cases for review by CDI specialists to quickly and efficiently identify meaningful CDI opportunities.

Care provider assignments to a patient may be automatically generated based on clinical evidence, documentation, workload, infectious status and other factors. The patient's chart may be accessed by a rules-based engine configured with rules to relate a patient's clinical status and needs to qualifications, certifications, capabilities and skills of care providers to select the care provider best qualified to assign to the patient. For instance, care providers having specialized training may be identified for assignment to patients presenting with specialized needs. Graphical displays of available providers may be displayed to and overridden by a manager. Because patient needs are automatically aligned with provider capabilities, availability and other factors, the errors, oversights and inefficiencies of manual or informal assignment systems are avoided and better health care delivery can be realized.

The invention discloses a compound composition of traditional Chinese medicine granules for regulating liver regeneration and prevention and treatment methods for chronic liver diseases by using the compound alone or in combination with antiviral medicine. The medicine is composed of: 5-30 parts of prepared Chinese foxglove root, 5-30 parts of virgate wormwood, 3-9 parts of turmeric, 3-12 parts of licorice, 3-15 parts of schisandra fruit, 5-15 parts of underleaf pearl, 5-30 parts of diffusa , 5-30 parts of poria, 5-30 parts of coix seed, 5-30 parts of salvia fruit, 1-10 parts of curcuma rhizome, 3-12 parts of dodder, and 5-15 parts of mistletoe For people suffering from chronic liver diseases (drug-induced liver disease, alcoholic or non-alcoholic fatty liver disease, autoimmune liver disease, viral hepatitis, etc.) which have high risk of liver failure, liver cirrhosis, and liver cancer, and people suffering from liver cancer or people after liver cancer surgery, clinical and experimental evidences show that the traditional Chinese medicine granules have synergies of regulation of liver regeneration and anti-virus, anti-liver injury, anti-liver fibrosis, and liver cancer prevention, and a relatively high level of clinical evidence based medicine evidences are obtained.

The invention discloses a compound Chinese medicinal composition for treating hog cholera and a preparation method thereof, relating to the field of animal medicines. The preparation method comprises the following steps of: (1) sieving all components (except interferon) in the prescription with a 500-mesh sieve after ultra-fine pulverization; (2) taking 15-25 parts of propolis, 3-10 parts of interferon for pigs, 10-25 parts of Cyrtomium fortune and 15-25 parts of selfheal according to weight part and mixing for 5-10 minutes until well mixing; (3) taking 10-20 parts of gypsum, 10-250 parts of dandelion, 10-25 parts of rhizoma anemarrhenae and 15-30 parts of rhubarb according to weight part and mixing for 5-10 minutes until well mixing; (4) combining the compositions prepared in the steps (2) and (3), continuing to mix for 10-15 minutes until well mixing. The invention has the beneficial effects of rational prescription and simple preparation; the composite has the advantages of no toxic effect, no pollution, no drug residue and no drug resistance, ultra-micro pulverization, high bioavailability, obvious curative effect and special effect for treating hog cholera through the clinical evidence.

The invention relates to oral liquid for treating canine distemper. The oral liquid is prepared by mixing and extracting the following components in parts by weight: 15 to 35 parts of sanguisorba officinalis, 15 to 25 parts of flos sophorae, 15 to 35 parts of herba taching, 15 to 25 parts of rhizoma coptidis, 15 to 25 parts of radix curcumae, 15 to 35 parts of fructus mume, 20 to 40 parts of honeysuckle, 10 to 20 parts of angelica, 15 to 25 parts of liquorice, and 5 to 10 parts of ribavirin. The oral liquid has the beneficial effects of being reasonable in composition and simple to prepare, being capable of looking into both root causes and symptoms by combination of traditional Chinese medicines and western medicines, achieving high biological availability, having a greatly remarkable curative effect, and having a special effect on treating the canine distemper according to clinical evidence.

The invention discloses application of metallothionein-1 in the preparation of drugs for inhibiting rheumatoid arthritis. The metallothionein-1 inhibits the differentiation of Th17 cells, promotes the differentiation of regulatory T cells, regulates the balance of Th17 / Treg under the state of CIA, and participates in the generation and development of rheumatoid arthritis; and the metallothionein-1 inhibits the expression of various inflammatory factors related to rheumatoid arthritis by a negative feedback regulation mechanism, and promotes the expression of immune suppression factors (IL-10 and TGF-beta) by a positive feedback regulation mechanism, and therefore, inflammatory response and pathologic change of rheumatoid arthritis are reduced, the process of the rheumatoid arthritis is delayed, and clinical evidence and a drug target are provided for the diagnosis and treatment of autoimmune diseases related to rheumatoid arthritis.

The invention discloses a guidance system for immune checkpoint inhibitor treatment medication. The system comprises an immune checkpoint inhibitor related biomarker interpretation system and a construction method thereof, a medication guidance adaptation method and device and a storage medium, wherein the construction method of the interpretation system comprises the steps: obtaining public dataresources which comprise biomarker information related to tumor immune checkpoint inhibitor treatment and the like; screening and classifying the public data resources, and determining the key fieldsand attributes of information to be input into the interpretation system; carrying out grade classification on the immune checkpoint inhibitor related clinical evidence information; establishing a structural framework of the interpretation system; and inputting the key field information into a corresponding field position of the interpretation system structure framework according to a unified standardized input rule. According to the method, the problems that in the immune checkpoint inhibitor treatment medication guidance process, the scattered data, incomprehensive data collection, tedious query procedures, and inaccurate medication guidance caused by the fact that immune checkpoint inhibitor medication recommendation has no priority, are solved.

The invention relates to secretio bufonis injection for treating yellow and white scour of newborn piglets. The secretio bufonis injection is prepared by mixing the following components in parts by weight: 5 to 15 parts of venenum bufonis, 25 to 75 parts of ethanol with concentration of 95%, 1 to 3 parts of benzyl alcohol, 2.5 to 7.5 parts of anhydrous sodium sulfite, 2.5 to 7.5 parts of activated carbon, and 899.5 to 966.5 parts of distilled water for injection. The secretio bufonis injection has the beneficial effects of being reasonable in composition and simple to prepare, being free from toxic and side effects, drug residues and tolerance, having a greatly remarkable curative effect, and having a special effect on treating the yellow and white scour of newborn piglets according to clinical evidence.

The invention provides application of a mycoplasma hyopneumoniae antigen or an immunogenic composition containing the antigen in prevention and treatment of PRDC (porcine respiratory disease complex) and diseases with PRDC relevant clinical evidence. Specifically, the application includes immunization of pigs with an immune dosage of the mycoplasma hyopneumoniae antigen or the immunogenic composition containing the mycoplasma hyopneumoniae antigen. Vaccination with vaccines containing the mycoplasma hyopneumoniae antigen on animals can significantly alleviate and reduce the severity and duration of PRDC relevant clinical evidence.

The invention provides a pharmaceutical composition capable of relaxing muscles and tendons and relieving pain. The pharmaceutical composition comprises, by weight, 5-8 parts of himalayan teasel roots, 2-4 parts of curcumae rhizome, 6-7 parts of radix millettiae speciosae, 8-9 parts of eucommia ulmoides, 10-12 parts of divaricate saposhniovia roots, 5-6 parts of pubescent holly roots, 3-4 parts of safflower, 2-3 parts of roots of doubleteeth pubescent angelica, 5-6 parts of myrrh, 1-2 parts of radix clematidis, 12-14 parts of shinyleaf pricklyash roots, 5-6 parts of wintergreen oil, 8-9 parts of menthol, 4-23 parts of turpentine oil and 5-6 parts of camphor; compared with the prior art, the pharmaceutical composition has the advantages that according to repeated experiments and clinical evidence, the pharmaceutical composition has good effects on relieving soreness of waist, backache, tendon-and-muscle shrinkage, dizziness, fever, cold, chest pain, stomachache, and abdominal pain. The pharmaceutical composition can be used in a long term.

A "binary-categorical differentiation" method for finding a combination of a small number of exquisite DNA methylation positions in the human genome (CG IDs) for detecting cancer in DNA in biologicalmaterial derived from a patient and distinguish it from other tissue cell free DNA and blood cells DNA. Another method for detecting tissue of origin of tumor DNA uses a combination of unique DNA methylation positions in the human genome (CG IDs). Combinations of CG IDs derived from tumor DNA are disclosed for accurately detecting with cancers by measuring the DNA methylation of a combination of specific CG IDs and deriving a "methylation score". Kits for predicting cancer using CG IDs using multiplexed next generation sequencing methylation assays, pyrosequencing assays and methylation specific PCR from a small volume of plasma. Various methods using biological material help lead to prediction of cancer in persons with no other clinical evidence for cancer.

The invention relates to the field of animal medicines, and particularly relates to a compound propolis combination for treating swine erysipelas. The compound propolis combination is prepared by mixing the following components in parts by weight: 15 to 35 parts of propolis, 15 to 35 parts of rheum officinale, 15 to 35 parts of burdock, 15 to 35 parts of herba taching, 15 to 45 parts of gentiana scabra bge, 15 to 35 parts of cortex moutan, 15 to 40 parts of liquorice, 15 to 45 parts of cape jasmine fruit, 15 to 45 parts of pericarpium citri reticulatae, and 15 to 45 parts of fructus forsythia. The compound propolis combination has the beneficial effects of being reasonable in composition and simple to prepare, being free from toxic and side effects, pollution, drug residues and tolerance, achieving high biological availability as being subjected to superfine grinding, having a greatly remarkable curative effect, and having a special effect on treating the swine erysipelas according to clinical evidence.

Computer based methods, systems, and computer readable media for intelligently accessing various types of pharmaceutical information in a content repository and ranking drugs at the variant level, gene level, and pathway level. In some cases, drugs that target the same gene, gene variant, or biological pathway may be ranked based upon in vitro, pre-clinical, clinical, or post-clinical evidence. To determine ranking of a plurality of drugs, information pertaining to drug administration is analyzed for the drugs. For a plurality of drugs, attributes corresponding to the drug are determined, wherein the attributes include a variant or a gene targeted by the drug, and a biological pathway comprising the targeted variant or gene. The plurality of drugs are ranked according to a drug effectiveness score based on one or more of a determined efficacy, potency, or toxicity.

The present invention provides clinical evidence for a method of stem cell transplantation that facilitates engraftment and reconstitutes immunocompetence of the recipient without requiring myeloablative conditioning.

Computerized systems and methods identify deficiencies in patient data that may impact payment for services rendered to a patient and facilitates collection / correction of patient data to address the deficiencies. The deficiencies occur in two main situations: (1) a physician has confirmed a diagnosis that impacts payment but the patient data does not satisfy clinical evidence, direct evidence, and treatment requirements to support the diagnosis; and (2) the patient data satisfies clinical evidence, direct evidence, and treatment requirements to support a diagnosis but a physician has not confirmed the diagnosis. When a deficiency is identified, an electronic notice is generated and delivered over a communication network to a clinician computing device. The notice may provide the clinician access to a user interface that allows the clinician to enter additional information or clarify information in the patient data to address the deficiency.

The invention discloses a traditional Chinese medicine for treating chronic cardiac insufficiency, sick sinus syndrome, ischemic angina pectoris, coronary heart disease and the like, and a preparation method thereof. When the traditional Chinese medicine disclosed by the invention is used for clinical evidence, for deficiency of the heart and kidney-yin and stagnation of heart meridian by differentiation of symptoms and signs of traditional Chinese medicine, the total effective rate for treating congestive heart failure is 88.89%, the total effective rate for treating sick sinus syndrome is 85%, and the total effective rate for treating coronary heart disease caused angina pectoris is 90%. The traditional Chinese medicine is a multi-target good medicine convenient and easy to use for heart, and has conformance to the integral function of the heart. The invention is characterized in that the traditional Chinese medicine is a new medicine which is triggered by symptoms of disease, has a compliance mode of action, is capable of better adjusting the continuous coupling function of the heart, and is favorable to the comprehensive recovery and reconstruction of the integral function of the heart. The medicament disclosed by the invention has the following characteristics of exciting the pacemaker when the pacemaker is weak, strengthening the cardiac efficiency when the myocardial contractive power is weak, improving microcirculation and promoting tissue reconstruction and function recovery when the coronary flow is small, and the like, and the medicament is suitable for all kinds of heart diseases and favorable to comprehensive and integral function recovery of the heart.

The invention discloses a compound composition of traditional Chinese medicine granules for regulating liver regeneration and prevention and treatment methods for chronic liver diseases by using the compound alone or in combination with antiviral medicine. The medicine is composed of: 5-30 parts of prepared Chinese foxglove root, 5-30 parts of virgate wormwood, 3-9 parts of turmeric, 3-12 parts of licorice, 3-15 parts of schisandra fruit, 5-15 parts of underleaf pearl, 5-30 parts of diffusa , 5-30 parts of poria, 5-30 parts of coix seed, 5-30 parts of salvia fruit, 1-10 parts of curcuma rhizome, 3-12 parts of dodder, and 5-15 parts of mistletoe For people suffering from chronic liver diseases (drug-induced liver disease, alcoholic or non-alcoholic fatty liver disease, autoimmune liver disease, viral hepatitis, etc.) which have high risk of liver failure, liver cirrhosis, and liver cancer, and people suffering from liver cancer or people after liver cancer surgery, clinical and experimental evidences show that the traditional Chinese medicine granules have synergies of regulation of liver regeneration and anti-virus, anti-liver injury, anti-liver fibrosis, and liver cancer prevention, and a relatively high level of clinical evidence based medicine evidences are obtained.

The invention relates to a compound propolis combination for treating ox influenza. The compound propolis combination is prepared by mixing the following components in parts by weight: 15 to 35 parts of propolis, 15 to 35 parts of asarum, 15 to 35 parts of radix paeoniae rubra, 15 to 35 parts of artemisia capillaries, 15 to 45 parts of radix bupleuri, 15 to 35 parts of pinellia ternate, 15 to 40 parts of liquorice, 15 to 45 parts of pericarpium citri reticulatae, 15 to 45 parts of fructus aurantii, and 15 to 45 parts of notopterygium root. The compound propolis combination has the beneficial effects of being reasonable in composition and simple to prepare, being free from toxic and side effects, pollution, drug residues and tolerance, achieving high biological availability as being subjected to superfine grinding, having a greatly remarkable curative effect, and having a special effect on treating the ox influenza according to clinical evidence.

The invention relates to a compound propolis combination for treating ox influenza. The compound propolis combination is prepared by mixing the following components in parts by weight: 15 to 35 parts of propolis, 15 to 35 parts of asarum, 15 to 35 parts of radix paeoniae rubra, 15 to 35 parts of artemisia capillaries, 15 to 45 parts of radix bupleuri, 15 to 35 parts of pinellia ternate, 15 to 40 parts of liquorice, 15 to 45 parts of pericarpium citri reticulatae, 15 to 45 parts of fructus aurantii, and 15 to 45 parts of notopterygium root. The compound propolis combination has the beneficial effects of being reasonable in composition and simple to prepare, being free from toxic and side effects, pollution, drug residues and tolerance, achieving high biological availability as being subjected to superfine grinding, having a greatly remarkable curative effect, and having a special effect on treating the ox influenza according to clinical evidence.

The invention belongs to the technical field of traditional Chinese medicine preparation, and relates to a traditional Chinese medicinal composition for preventing and treating postpartum urinary retention as well as a preparation method and application thereof. The traditional Chinese medicinal composition is prepared from the following components in parts by weight: 3 to 30 parts of rhizoma zingiberis recens, 3 to 30 parts of fistular onion stalk, 0.5 to 5 parts of fine salt, 2 to 30 parts of raw radix astragali powder, 2 to 30 parts of poria cocos powder and 2 to 30 parts of motherwort herbpowder. Through half an hour of umbilical application, the traditional Chinese medicinal composition has a significant effect on preventing postpartum urinary retention, and greatly reduces the incidence of urinary retention. The traditional Chinese medicinal composition has a remarkable prevention effect, and the therapeutic effect is more obvious than that of neostigmine and other Western medicines. The traditional Chinese medicinal composition has no obvious toxic and side effects, is economical, practical and convenient to operate, shortens the hospitalization time of patients, can reducethe occurrence of post-operative urinary tract infection and postpartum hemorrhage, provides reliable clinical evidence for the popularization of application of traditional Chinese medicine to Shenque acupoint on umbilicus, and has clinical and basic medical institution popularization and application value.

The invention relates to a compound combination made from pure traditional Chinese medicines and used for treating henpox. The compound combination is prepared by mixing the following components in parts by weight: 15 to 35 parts of houttuynia cordata, 1 to 3 parts of calculus bovis factitious, 1 to 2 parts of venenum bufonis, 15 to 35 parts of borneol, 10 to 30 parts of boswellia carterii, 10 to 30 parts of myrrh, and 15 to 35 parts of rhizoma coptidis. The compound combination has the beneficial effects of being reasonable in composition and simple to prepare, being free from toxic and side effects, pollution, drug residues and tolerance, achieving high biological availability as being subjected to superfine grinding, having a greatly remarkable curative effect, and having a special effect on treating the henpox according to clinical evidence.

Computerized systems and methods identify deficiencies in patient data that may impact payment for services rendered to a patient and facilitates collection / correction of patient data to address the deficiencies. The deficiencies occur in two main situations: (1) a physician has confirmed a diagnosis that impacts payment but the patient data does not satisfy clinical evidence, direct evidence, and treatment requirements to support the diagnosis; and (2) the patient data satisfies clinical evidence, direct evidence, and treatment requirements to support a diagnosis but a physician has not confirmed the diagnosis. When a deficiency is identified, an electronic notice is generated and delivered over a communication network to a clinician computing device. The notice may provide the clinician access to a user interface that allows the clinician to enter additional information or clarify information in the patient data to address the deficiency.